|

Trastuzumab Rezetecan for Injection Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Jiangsu HengRui Medicine Co., Ltd.1

Indications

  • Breast Cancer2
  • Cancer2
  • Unresectable Locally Metastatic Breast Cancer1
  • Unresectable Locally Recurrent Breast Cancer1
  • Triple Negative Breast Cancer1

Other2 trials

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Phase 3
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.